 |
|
|
|
 |
|
|
| Article 1 to 10 out of 13 concerning TopoTarget A/S
|
-
TopoTarget completes the capital increase and the acquisition of Apoxis SA
(06/29/2007)
TopoTarget A/S announced the completion of the acquisition of Apoxis SA with 3,598,030 shares having been issued to the vendors of Apoxis. Hereby TopoTarget gains two oncology products to its pipeline. Consistent with the growth strategy pursued by ...
-
TopoTarget and CuraGen Initiate Phase II Trial of Belinostat (PXD101) in Combination with Velcade
(03/30/2007)
TopoTarget A/S and CuraGen Corporation announced the initiation of patient dosing in a Phase II open-label, multi-center clinical trial evaluating the efficacy and safety of intravenous belinostat (PXD101), a small molecule histone deacetylase ...
-
TopoTarget establishes TopoTarget USA, Inc. and employs experienced marketeer as President
(11/17/2006)
TopoTarget A/S announced the establishment of TopoTarget USA, Inc. to be located in Rockaway, New Jersey near the center of the east coast U.S. pharmaceutical industry. TopoTarget USA, Inc. is scheduled to launch the company's first oncology ...
-
TopoTarget and CuraGen Initiate NCI-Sponsored Phase II Trial of PXD101 for Ovarian Cancer
(11/16/2006)
TopoTarget A/S and CuraGen Corporation announced the initiation of patient dosing in a Phase II clinical trial evaluating the antitumor activity of intravenous PXD101, a small molecule histone deacetylase (HDAC) inhibitor, for the treatment of ...
-
Southwest Oncology Group Opens New Lymphoma Trial with CuraGen's and TopoTarget's PXD101
(08/28/2006)
CuraGen Corporation and TopoTarget A/S announced the Southwest Oncology Group, a national clinical trials cooperative group, has just opened a Phase II clinical trial to test the effects of a new investigational agent on aggressive B-cell lymphoma. ...
-
CuraGen and TopoTarget Initiate Clinical Program Evaluating Oral Administration of PXD101
(08/14/2006)
Phase I trial to establish the dose and frequency for oral PXD101 in patients with advanced solid tumors
CuraGen Corporation and TopoTarget A/S announced the initiation of a Phase I clinical trial evaluating the administration of oral PXD101, a small molecule histone deacetylase (HDAC) inhibitor, in patients with advanced solid tumors. The Phase I ...
-
CuraGen and TopoTarget Initiate NCI-sponsored Phase I Clinical Trial of PXD101 and Azacitidine
(08/10/2006)
CuraGen Corporation and TopoTarget A/S announced the initiation of patient dosing in a Phase I clinical trial evaluating the safety and tolerability of PXD101, a small molecule histone deacetylase (HDAC) inhibitor, in combination with azacitidine ...
-
CuraGen and TopoTarget Initiate Phase Ib/II Clinical Trial with PXD101 and Velcade(R) for Multiple Myeloma
(03/24/2006)
CuraGen Corporation and TopoTarget A/S announced the initiation of patient dosing in a Phase Ib/II proof-of-concept trial to evaluate PXD101, a small molecule histone deacetylase (HDAC) inhibitor, in combination with Velcade(R) (bortezomib) for the ...
-
CuraGen and TopoTarget Initiate Phase II Clinical Trial for treatment of T-Cell Lymphoma
(02/06/2006)
CuraGen Corporation and TopoTarget A/S announced the initiation of patient dosing in a Phase II clinical trial evaluating the efficacy and safety of PXD101, a small molecule histone deacetylase (HDAC) inhibitor, for the treatment of cutaneous T-cell ...
-
CuraGen and TopoTarget Initiate Phase Ib Clinical Trial with PXD101 for Advanced Colorectal Cancer
(09/29/2005)
Proof-of-Concept Trial Evaluating PXD101 Combination Therapy with 5- fluorouracil for Advanced Solid Tumors and Colorectal Cancer
CuraGen Corporation and TopoTarget A/S announced the initiation of patient dosing in a Phase Ib open-label, multi-center, proof-of-concept clinical trial evaluating PXD101, a small molecule histone deacetylase (HDAC) inhibitor, for the treatment of ...
Additional information
TopoTarget A/S
København Ø, Denmark
Company
|
|
|
|
|
|
Top
